US5858980A
(en)
*
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
IL113812A
(en)
*
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
WO1999041247A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Autoimmune, Inc. |
TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
PT2090583E
(pt)
|
1998-09-25 |
2011-09-14 |
Yeda Res & Dev |
Polipéptidos relacionados com o copolímero 1 para utilização a título de marcadores de massas moleculares e em terapêutica
|
US6800287B2
(en)
*
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
CN100360180C
(zh)
*
|
2000-01-20 |
2008-01-09 |
耶达研究及发展有限公司 |
共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
|
ZA200206457B
(en)
*
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
MXPA02008023A
(es)
*
|
2000-02-18 |
2005-06-30 |
Yeda Res & Dev |
Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
EP1292279A4
(en)
*
|
2000-06-05 |
2005-01-12 |
Teva Pharma |
USE OF GLATIRAMER ACETATE (COPOLYMER 1) FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
JP4328090B2
(ja)
*
|
2000-06-07 |
2009-09-09 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
神経細胞の保護療法におけるコポリマー1、関連ペプチドおよびポリペプチドならびにそれらによって処理されたt細胞の使用
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
AU6887101A
(en)
*
|
2000-06-20 |
2002-01-02 |
Caprion Pharmaceuticals, Inc. |
Copolymers and methods of treating prion-related diseases
|
IL137460A0
(en)
*
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
DE60237170D1
(de)
|
2001-12-04 |
2010-09-09 |
Teva Pharma |
Verfahren zur messung der wirkstärke von glatirameracetat
|
DK1429800T3
(da)
*
|
2001-12-06 |
2009-04-27 |
Yeda Res & Dev |
Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
|
AU2002360696A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
JP5291878B2
(ja)
|
2003-01-07 |
2013-09-18 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
治療的免疫のためのコポリマー1を含む点眼ワクチン
|
RU2339397C2
(ru)
*
|
2003-01-21 |
2008-11-27 |
Йеда Рисерч Энд Дивелопмент Ко.Лтд. |
Сор1 для лечения воспалительных заболеваний кишечника
|
EP1603530A1
(en)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
WO2004089407A2
(en)
|
2003-03-31 |
2004-10-21 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
KR20060097020A
(ko)
*
|
2003-10-31 |
2006-09-13 |
테바 파마슈티컬 인더스트리즈 리미티드 |
약물 전달용 나노입자
|
EP1684797A1
(en)
|
2003-11-12 |
2006-08-02 |
Yeda Research and Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
CA2548310C
(en)
|
2003-12-09 |
2014-02-18 |
Yeda Research And Development Co. Ltd. |
Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
|
AU2005211424A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Mixture Sciences, Inc. |
Peptide mixtures with immunomodulatory activity
|
RU2006134701A
(ru)
*
|
2004-03-01 |
2008-04-10 |
Пептиммьюн |
Способы и композиции для лечения аутоиммунных заболеваний
|
AU2005218625A1
(en)
*
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
ES2560448T3
(es)
|
2004-05-07 |
2016-02-19 |
Ares Trading S.A. |
Procedimientos de tratamiento de enfermedades con copolímeros aleatorios
|
EP2332569A3
(en)
|
2004-06-25 |
2011-09-14 |
ID Biomedical Corporation of Quebec |
Compositions and methods for treating neurological disorders
|
PL1797109T3
(pl)
*
|
2004-09-09 |
2016-11-30 |
|
Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
|
PL2361924T3
(pl)
*
|
2004-09-09 |
2014-08-29 |
Teva Pharma |
Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego
|
DE602005016292D1
(de)
*
|
2004-10-29 |
2009-10-08 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
AU2005308396B2
(en)
*
|
2004-11-29 |
2011-06-09 |
Yeda Research And Development Co. Ltd. |
Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
|
RU2419638C2
(ru)
*
|
2005-02-02 |
2011-05-27 |
Тева Фармасьютикал Индастриз, Лтд. |
Способ получения полипептидных смесей с использованием гидрогенолиза
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
CA2596664A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Teva Pharmaceutical Industries Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
EP1891233A4
(en)
*
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
WO2007081975A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
EP2016095A2
(en)
|
2006-04-13 |
2009-01-21 |
Peptimmune, Inc. |
Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
|
CN101479607B
(zh)
*
|
2006-04-28 |
2013-10-02 |
莫门塔制药股份有限公司 |
评估肽混合物的方法
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
ES2605154T3
(es)
|
2006-06-28 |
2017-03-13 |
Yeda Research And Development Company Limited |
Copolímero 1 para el tratamiento de la degeneración macular relacionada con la edad
|
US20080021192A1
(en)
*
|
2006-07-05 |
2008-01-24 |
Momenta Pharmaceuticals, Inc. |
Process for the preparation of copolymer-1
|
US8753833B2
(en)
|
2007-06-21 |
2014-06-17 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
EP2173766A1
(en)
*
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
AP3467A
(en)
|
2007-10-16 |
2015-11-30 |
Peptimmune Inc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
WO2009062132A2
(en)
|
2007-11-09 |
2009-05-14 |
California Institute Of Technology |
Immunomodulating compounds and related compositions and methods
|
AU2008330093A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Yeda Research And Development Co., Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
RU2010146489A
(ru)
*
|
2008-04-16 |
2012-05-27 |
Момента Фармасьютикалз, Инк. (Us) |
Анализ композиций сополимера аминокислот
|
HUE025042T2
(en)
*
|
2008-08-07 |
2016-07-28 |
Sigma Aldrich Co Llc |
High-yield production of low molecular weight polylysine and poliornitine
|
AU2009279636A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
US9617313B2
(en)
*
|
2008-12-24 |
2017-04-11 |
Synthon Bv |
Process for purifying a polymer mixture
|
WO2010115175A1
(en)
|
2009-04-03 |
2010-10-07 |
Momenta Pharmaceticals, Inc. |
Control of copolymer compositions
|
US9150609B2
(en)
|
2009-06-04 |
2015-10-06 |
Council Of Scientific & Industrial Research |
Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
|
PT2275086E
(pt)
|
2009-07-15 |
2012-05-18 |
Teva Pharma |
Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
LT2630962T
(lt)
|
2009-08-20 |
2018-10-25 |
Yeda Research & Development Company, Ltd. |
Mažo dažnio glatiramero acetato terapija
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
PT3536333T
(pt)
|
2010-01-04 |
2022-11-11 |
Mapi Pharma Ltd |
Sistema de depósito compreendendo acetato de glatirâmero
|
US20130035390A1
(en)
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
JP6027961B2
(ja)
|
2010-04-07 |
2016-11-16 |
シェン, ユエSHEN, Yue |
粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
|
US20130281663A1
(en)
*
|
2010-04-27 |
2013-10-24 |
Dr. Reddy's Laboratories, Inc. |
Preparation of polypeptides and salts thereof
|
WO2011146910A1
(en)
|
2010-05-20 |
2011-11-24 |
Round June L |
Antigen specific tregs and related compositions, methods and systems
|
US9109006B2
(en)
*
|
2010-07-29 |
2015-08-18 |
Santhanakrishnan Srinivasan |
Glatiramer acetate molecular weight markers
|
KR20140019296A
(ko)
|
2010-10-11 |
2014-02-14 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
|
EP2675824B1
(en)
|
2011-02-14 |
2017-09-27 |
USV Private Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
EP2699317B1
(en)
*
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
US9539281B2
(en)
|
2011-07-12 |
2017-01-10 |
The Brigham And Women's Hospital, Inc. |
Lipid-containing PSA compositions, methods of isolation and methods of use thereof
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
CA2851510A1
(en)
|
2011-10-10 |
2013-04-18 |
Teva Pharmaceutical Industries Ltd. |
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
PT2774640E
(pt)
|
2013-03-08 |
2015-02-09 |
Teva Pharma |
Dispositivo injector reutilizável para seringa
|
PL2774639T3
(pl)
|
2013-03-08 |
2015-07-31 |
Teva Pharma |
Wielorazowe urządzenie strzykawkowe dla strzykawki
|
JP6553018B2
(ja)
|
2013-03-14 |
2019-07-31 |
マイラン・インコーポレイテッドMylan Inc. |
酢酸グラチラマー応答バイオマーカーmRNA効力アッセイ
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
CA2911826C
(en)
|
2013-05-10 |
2022-08-23 |
California Institute Of Technology |
Probiotic prevention and treatment of colon cancer
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
CA2928084A1
(en)
|
2013-10-24 |
2015-04-30 |
Mylan Inc. |
Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
US10545144B2
(en)
|
2013-12-31 |
2020-01-28 |
Yeda Research And Development Co., Ltd. |
Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
|
US10144778B2
(en)
|
2014-03-12 |
2018-12-04 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
EP3265814B1
(en)
|
2015-03-01 |
2020-11-18 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
US11331335B2
(en)
|
2015-06-10 |
2022-05-17 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
EP3337321A4
(en)
|
2015-08-19 |
2019-07-17 |
President and Fellows of Harvard College |
LIPIDED PSA COMPOSITIONS AND METHOD
|
EP3147667B1
(en)
|
2015-09-24 |
2019-06-12 |
CHEMI S.p.A. |
Analysis of the molecular weight distribution of complex polypeptide mixtures
|
ES2707500T3
(es)
|
2015-11-23 |
2019-04-03 |
Chemi Spa |
Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
US20210220428A1
(en)
|
2016-06-30 |
2021-07-22 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
CA3030974A1
(en)
|
2016-07-15 |
2018-01-18 |
President And Fellows Of Harvard College |
Glycolipid compositions and methods of use
|
EP3503907B1
(en)
|
2016-08-28 |
2024-03-13 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
PT3506921T
(pt)
|
2016-08-31 |
2023-08-07 |
Mapi Pharma Ltd |
Sistemas de libertação controlada que compreendem acetato de glatirâmero
|
JP2020515530A
(ja)
|
2017-03-26 |
2020-05-28 |
マピ ファーマ リミテッド |
進行型の多発性硬化症を治療するためのグラチラマーデポシステム
|
US11413311B2
(en)
|
2017-05-15 |
2022-08-16 |
Mapi Pharma Ltd. |
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
|
AU2018270396A1
(en)
|
2017-05-15 |
2020-01-02 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
EP3765034A1
(en)
|
2018-03-12 |
2021-01-20 |
Yeda Research and Development Co. Ltd |
Treatment of a heart disease
|